#pharmaceutical-pipeline

[ follow ]
#eli-lilly #glp-1 #financial-growth #dividends #analyst-downgrades #valuation-compression
Business
from24/7 Wall St.
2 days ago

This Pharma Stock Keeps Earning My Money, Here's Why

Eli Lilly's strong growth in the GLP-1 market and solid financials drive continued investment confidence.
Business intelligence
from24/7 Wall St.
1 month ago

Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit

Multiple analysts downgraded or adjusted targets on Novo Nordisk, Korn Ferry, Jefferies Financial Group, and Talkspace due to pipeline disappointment, valuation compression, clinical trial underperformance, and acquisition-driven resolution.
fromwww.theguardian.com
7 months ago

Pharma shake-up: Surprise change of CEO at GSK, as AstraZeneca announces New York stock market listing business live

GSK tells investors: Luke is a highly respected, experienced global biopharma leader, having worked at senior levels in the US, Europe and Asia, at AstraZeneca, Roche and Sanofi-Aventis, prior to joining GSK. This experience, and significant contribution to GSK, mean he is exceptionally well-qualified to lead the company, and to deliver the patient and shareholder value inherent in the company's future ambitions.
Business
[ Load more ]